Spruce Biosciences, Inc.
NASDAQ:SPRBBiotechnology
+$2.47 today
- Market cap
- $117.37M
- Beta
- 3.20
- P/E (TTM)
- -1.9
- EPS (TTM)
- -$27.11
Volume 0.06M
Average 0.06M
SPRB Total Current Liabilities
All obligations due within one year.
Spruce Biosciences, Inc.NASDAQ: SPRB
Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total current liabilities falls 24.8% from a year ago
Total current liabilities stood at $11.78M at the end of Q1 FY2026, down 24.8% from a year earlier and up 16.8% from the prior quarter. Over 3 fiscal years it compounded at -6.8% a year.
Context
- Total current liabilities amounted to 21.0% of total assets at the end of Q1 FY2026, down 28.5 pp from a year earlier.
- Total current liabilities increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total current liabilities keeps falling in the next quarterly balance sheet after a -24.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 10.09M USD
- Year-over-year change
- -33.8%
- 4-year CAGR
- +3.3%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 10.09M | -33.8% |
| FY2024 | 2024-12-31 | 15.25M | -37.7% |
| FY2023 | 2023-12-31 | 24.47M | +96.6% |
| FY2022 | 2022-12-31 | 12.45M | +40.3% |
| FY2021 | 2021-12-31 | 8.87M | — |
Total Current Liabilities vs competitors
How SPRB compares with its peers on the latest reported figures
- SPRB's Mar 2026 total current liabilities of $11.78M is the 4th highest of the 9 companies compared; the peer median is $7.63M.
- Its year-over-year change of -24.8% is the 5th highest of 9, against a peer median of -33.7%.
- Total current liabilities amounts to 21.0% of total assets for SPRB, versus a peer median of 28.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $38.88M | +56.6% | +32.4% | 177.6% | |
| Mar 2026 | $25.18M | -23.1% | +22.4% | 211.5% | |
OSTXOS Therapies Incorporated | Mar 2026 | $16.95M | +379.4% | +24.2% | 232.3% |
| Mar 2026 | $11.78M | -24.8% | -6.8% | 21.0% | |
| Jun 2026 | $7.86M | -48.2% | +14.6% | 32.6% | |
| Mar 2026 | $7.39M | -52.3% | +5.3% | 23.9% | |
| Mar 2026 | $6.88M | +59.4% | -4.8% | 7.0% | |
| Mar 2026 | $3.35M | -44.3% | -54.9% | 5.3% | |
| Mar 2026 | $1.82M | -67.8% | -6.6% | 9.2% | |
| Peer median (excluding SPRB) | $7.63M | -33.7% | +10.0% | 28.2% | |
Competitors are the stored peer set for SPRB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 42.75M | 24.49M | 96.34M | 38.75M | 48.91M |
| Short-term Investments | 46.22M | 54.59M | 0 | 0 | 0 |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 396K | 1.21M | 1.97M | 2.28M | 2.85M |
| Total Current Assets | 91.9M | 83.61M | 102.18M | 44.21M | 52.11M |
| Property, Plant & Equipment (Net) | 1.48M | 1.4M | 1.18M | 934K | 666K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 32.46M | (54.54M) | 0 | 0 | 36K |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 653K | 55.18M | 582K | 69K | 207K |
| Total Non-current Assets | 34.59M | 2.04M | 1.76M | 1M | 909K |
| Total Assets | 126.49M | 85.65M | 103.95M | 45.21M | 53.02M |
| Account Payables | 2.82M | 1.43M | 3.33M | 1.3M | 943K |
| Short-term Debt | 0 | 1.62M | 1.62M | 1.62M | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 4.91M | 0 | 0 |
| Other Current Liabilities | 1.44M | 1.29M | 11.25M | 882K | 1.77M |
| Total Current Liabilities | 8.87M | 12.45M | 24.47M | 15.25M | 10.09M |
| Long-term Debt | 4.88M | 3.29M | 1.72M | 124K | 419K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 73K | 161K | 236K | 282K | 0 |
| Total Non-current Liabilities | 6.24M | 4.72M | 2.97M | 1.14M | 419K |
| Total Liabilities | 15.12M | 17.16M | 27.44M | 16.39M | 10.51M |
| Common Stock | 3K | 3K | 4K | 4K | 0 |
| Retained Earnings | (103.13M) | (149.31M) | (197.23M) | (250.27M) | (289.23M) |
| Accumulated OCI | (184K) | (558K) | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 111.37M | 68.49M | 76.51M | 28.82M | 42.52M |
| Total Debt | 6.53M | 6.32M | 4.61M | 2.77M | 736K |
| Net Debt | (36.22M) | (18.17M) | (91.73M) | (35.99M) | (48.17M) |
Spruce Biosciences, Inc.
NASDAQ:SPRB
Intrinsic Alpha fair value
Locked
Current Price
$40.84
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.